外周血T细胞亚群计数与恶性肿瘤的相关性研究
Study on the correlation between T-lymphocyte subgroup count of peripheral blood and malignant tumor
-
摘要: 目的:探讨外周血T细胞亚群计数在恶性肿瘤中临床意义。方法:采用流式细胞术检测80例恶性肿瘤病人和100名健康体检者外周血CD3+、CD4+和CD8+细胞计数以及CD4+/CD8+比值。结果:恶性肿瘤病人CD3+、CD4+、CD8+细胞计数及CD4+/CD8+比值均较健康人群显著降低(P<0.01)。亚组分析结果显示,各恶性肿瘤组的CD3+和CD4+细胞计数均较对照组下降(P<0.05~P<0.01),CD8+细胞计数与对照组比较差异均无统计学意义(P>0.05),仅肺癌组CD4+/CD8+比值低于对照组(P<0.05);首诊组和进展组恶性肿瘤病人的所有观察指标差异均无统计学意义(P>0.05);男性恶性肿瘤病人的CD4+细胞计数低于女性病人(P<0.05)。结论:恶性肿瘤病人的CD3+、CD4+、CD8+细胞水平以及CD4+/CD8+比值存在一定程度的失衡,通过检测这些指标,可以了解病人机体的免疫状态,直接或者间接为肿瘤的免疫治疗提供依据。Abstract: Objective: To investigate the clinical significance of T-lymphocyte subgroup count of peripheral blood in malignant tumor.Methods: The amount of CD3+ cells,CD4+ cells,CD8+ cells and ratio of CD4+/CD8+ of peripheral blood in 80 malignant tumor patients and 100 healthy people were determined by flow cytometry.Results: Compared with healthy people,the amount of CD3+ cells,CD4+ cells,CD8+ cells and ratio of CD4+/CD8+ in patients with malignant tumor were significantly decreased(P<0.01).The results of subgroup analysis showed that the counts of CD3+ cells and CD4+ cells in malignant tumor patients decreased compared with control group(P<0.05 to P<0.01),the difference of the count of CD8+ cells between two groups was not statistically significant(P>0.05),and ratio of CD4+/CD8+ in lung cancer group was lower than that in control group(P<0.05).The difference of the parameter of malignant tumor patients between the first diagnosis group and progression group was not statistically significant(P>0.05).The amount of CD4+ cells in amale patients was lower than that in female patients(P<0.05).Conclusions: The imbalance of the counts of CD3+ cells,CD4+ cells,CD8+ cells and ratio of CD4+/CD8+ in malignant tumor patients are identified,which can be used to evaluate the immunity status of tumor patients,and provide a scientific evidence in immunotherapy of tumor.
-
Key words:
- tumor,malignance /
- T cell /
- flow cytometry
-
[1] ŠŤASTNÝ M,ŘÍHOVÁ B.Escape strategies of tumors from immune surveillence[J].Klin Onkol,2015,28 Suppl 4:4S28. [2] GFELLER D,BASSANI-STERNBERG M,SCHMIDT J,et al.Current tools for predicting cancer-specific T cell immunity[J].Oncoimmunology,2016,5(7):e1177691. [3] MOHME M,RIETHDORF S,PANTEL K.Circulating and disseminated tumour cells-mechanisms of immune surveillance and escape[J].Nat Rev Clin Oncol,2017,14(3):155. [4] LIU C,WORKMAN CJ,VIGNALI DA.Targeting regulatory T cells in tumors[J].FEBS J,2016,283(14):2731. [5] DIMELOE S,BURGENER AV,GRAHLERT J,et al.T-cell metabolism governing activation,proliferation and differentiation;a modular view[J].Immunology,2017,150(1):35. [6] FREY AB.Suppression of T cell responses in the tumor microenvironment[J].Vaccine,2015,33(51):7393. [7] LAIDLAW BJ,CRAFT JE,KAECH SM.The multifaceted role of CD4(+) T cells in CD8(+) T cell memory[J].Nat Rev Immunol,2016,16(2):102. [8] KWAK Y,KOH J,KIM DW,et al.Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer[J].Oncotarget,2016,7(49):81778. [9] LI Y,WU Z,LI J,et al.CD4(+)/CD8(-) T-cell large granular lymphocytic leukemia:one case report and literatures reviews[J].Zhonghua Xue Ye Xue Za Zhi,2015,36(9):739. [10] CAZA T,LANDAS S.Functional and Phenotypic Plasticity of CD4(+) T Cell Subsets[J].Biomed Res Int,2015,2015:521957. [11] KAPUR LH,KHALED Y,SOLH M,et al.De novo CD3 negative hepatosplenic T-cell lymphoma:diagnostic challenges and pitfalls[J].Arch Pathol Lab Med,2014,138(7):969. [12] LI L,YANG L,WWANG L,et al.Impaired T cell function in malignant pleural effusion is caused by TGF-β derived predominantly from macrophages[J].Int J Cancer,2016,139(10):2261. [13] KANG X,ZHANG X,LIU Z,et al.Granulocytic myeloid-derived suppressor cells maintain feto-maternal tolerance by inducing Foxp3 expression in CD4+CD25-T cells by activation of the TGF-beta/beta-catenin pathway[J].Mol Hum Reprod,2016,22(7):499. [14] 严健,原永明,张舒,等.CD3+、CD4+、CD8+T淋巴细胞亚群在肿瘤患者外周血中检测的临床意义[J].检验医学,2013,28(10):901. [15] SUKARI A,NAGASAKA M,AL-HADIDI A,et al.Cancer Immunology and Immunotherapy[J].Anticancer Res,2016,36(11):5593.
计量
- 文章访问数: 3927
- HTML全文浏览量: 517
- PDF下载量: 23
- 被引次数: 0